Genetics Factors Contributing to Body Weight in Anorexia Nervosa And

Total Page:16

File Type:pdf, Size:1020Kb

Genetics Factors Contributing to Body Weight in Anorexia Nervosa And Genetics Factors Contributing to Body Weight in Anorexia Nervosa and Bulimia Nervosa by Zeynep Yilmaz A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy (PhD) Institute of Medical Science University of Toronto © Copyright by Zeynep Yilmaz (2013) Genetic Factors Contributing to Body Weight in Anorexia Nervosa and Bulimia Nervosa Zeynep Yilmaz Doctor of Philosophy (PhD) Institute of Medical Science University of Toronto 2013 Abstract Anorexia nervosa (AN) is an eating disorder (ED) with substantial morbidity and the highest mortality among psychiatric disorders. Low body mass index (BMI) is the sine qua non of AN, and behaviours associated with reaching it are the primary reason for AN’s high morbidity and mortality. Low BMI is also the main criterion diagnostically separating AN from bulimia nervosa (BN). The aim of this dissertation was to determine the role of genes regulating weight and appetite in BMI in AN and BN. Study 1 utilized carefully selected DNA samples to explore the role of markers in the leptin, melanocortin, and neurotrophin system genes with known or putative function in AN, BN, and controls, as well as in lifetime BMIs in EDs. Study 2 investigated dopamine pathway genes and FTO in weight regulation in a large sample of AN cases. The results revealed that an MC4R variant linked to antipsychotic-induced weight gain was underrepresented in AN, and AGRP and NTRK2 genetic variants were linked to minimum BMI in AN and maximum BMI in BN, respectively. In Study 2, a significant association between FTO and BMI at recruitment was observed. To our knowledge, this is the first study to utilize two distinct but complementary genetic approaches in the study of weight in EDs. These genetic findings ii may serve as an important first step toward gaining a better understanding of weight regulation in AN and BN, as well as having the potential for developing more effective treatment options and providing a highly specific target for novel medications. Alongside this work, other ED genetic studies utilizing different clinical phenotypes were also carried out during my PhD, and the papers published are inserted as appendices for reasons of thematic unity. iii Acknowledgements First and foremost, I would like to thank my primary PhD supervisor Dr. Allan S. Kaplan, to whom I am forever indebted for his mentorship, encouragement, guidance and support with my research and career path, as well as for his unwavering faith in me even during the times I doubted my own abilities. I would also like to thank my PhD co-supervisor Dr. James L. Kennedy for sharing his vast expertise in psychiatric genetics and warmly welcoming me to his Neurogenetics family. I am grateful for the tremendous expertise, guidance, and support of my Program Advisory Committee members Drs. Robert D. Levitan and Jo Knight. Thank you to Dr. Caroline Davis for being a wonderful external resource and supportive collaborator. I would also like to acknowledge the examiners who have participated in my PhD transfer exam and defense: Drs. Brenda Toner, Gary Rodin, Franco Vaccarino, Lucy Osborne, and Howard Steiger. This PhD project would not have happened without the support of the Price Foundation Consortium and Genetic Consortium for Anorexia Nervosa. I would like to thank Drs. Andrew W. Bergen, Walter H. Kaye, Pierre Magistretti, Hakon Hakonarson, and the Price Foundation collaborators for making my PhD possible. I would also like to acknowledge Mme Luciana Price for generously funding this genetic consortium in an era when eating disorders were not thought to have a strong genetic basis. As for the Genetic Consortium for Anorexia Nervosa, I am grateful for the guidance and endless support of Dr. Cynthia M. Bulik. Thank you to the GCAN collaborators, as well as Drs. Laura M. Thornton, Patrick F. Sullivan, and Eleftheria Zeggini for their contributions. Thank you to the Canadian Institutes of Health Research for funding me throughout my graduate studies, Centre for Addiction and Mental Health/Government of Ontario AHSC AFP Innovation Fund and Ontario Mental Health Foundation for their grant support. I would also like to thank all the patients, without whom this research would not be possible. iv Members of the Neurogenetics Laboratory, Clinical Research Department, and Institute of Medical Science (IMS) have been a great source of support throughout my PhD. I would like to thank the postdoctoral fellows who made this work possible and for showing me how to be a scientist with integrity: Dr. Clement Zai for being a brilliant mentor and teaching me everything I know about genetic analysis, Dr. Arun Tiwari for always making time for me and his tremendous help with the selection of functional markers, and Dr. Vanessa Gonçalves for her support, inspiration, and opening my eyes to new research horizons. I would also like to acknowledge the following present or past members of the Neurogenetics Lab for their assistance and support: Nabilah Chowdhury, Sarah Gagliano, Sajid Shaikh, Natalie Freeman, Dr. Renan Souza, Ryan Tong, Daniel Felsky, Matthew Lau, Dr. Vincenzo de Luca, Maria Tampakeras, Olga Likhodi, David Sibony, and David Irwin. Thank you to my clinical manager Susan Dickens, as well as to Andrea Smart, Mary Smirniw, and Jinoos Sotodeh for administrative assistance. I am grateful for the support of current and past IMS staff: Hazel Pollard, Kamila Lear, Dianne Fukunaga, Kaki Narh, Marika Galadza, Michelle Rosen, Elena Gessas, Rejeanne Puran, and Sezen Mert, as well as current and past IMS graduate coordinators: Drs. Mary Seeman, Howard Mount, Vasundara Venkateswaran, Cindi Morshead. Mingyao Liu, and Karen Davis. Many thanks to Laura Mackew and Michael Verdirame for volunteering their time to assist me with literature searches. On a personal note, I am thankful for the unwavering friendship and endless support of Akshita Kapila Vincent, Alan Liang, Sara Piran, and Shahad Abdulnour. Thank you to the members of Yilmaz, Turgut, and Walhelm families. Last but definitely not least, I would like to thank my father Nurettin Yilmaz, my mother Gulsen Yilmaz (née Turgut), my spouse Antti Walhelm, and my late grandmother Sidika Turgut for their unconditional love, encouragement, sacrifices, support, and faith in my abilities. To them I dedicate this work. v Table of Contents Chapter Section Title Page Abstract .................................................................................................................... ii Acknowledgements ................................................................................................. iv Table of Contents ..................................................................................................... vi List of Abbreviations ............................................................................................... x List of Tables ........................................................................................................... xiv List of Figures .......................................................................................................... xvi List of Appendices.................................................................................................... xvii 1 INTRODUCTION............................................................................................. 1 1.1. Individual, Collective, and Financial Burden of Anorexia Nervosa and Bulimia Nervosa ................................................................................ 1 1.2. Diagnostic Criteria for AN and BN ......................................................... 3 1.2.1. DSM-IV Criteria for AN ............................................................................ 5 1.2.2. DSM-IV Criteria for BN ............................................................................. 5 1.3. Clinical Phenotypes Associated with AN and BN .................................. 6 1.3.1. Depression and Anxiety .............................................................................. 6 1.3.2. Substance Use/Abuse ................................................................................. 8 1.3.3. Personality and Temperament .................................................................... 8 1.3.4. Attention-Deficit/Hyperactivity Disorder.................................................... 9 1.4. Epidemiology of AN and BN ................................................................... 10 1.5. Outcome of AN and BN ........................................................................... 11 1.6. The Current State of Psychiatric Genetics ............................................. 13 1.7. Genetics of AN and BN ............................................................................ 16 1.7.1. Heritability .................................................................................................. 17 1.7.2. Linkage Studies .......................................................................................... 18 1.7.3. Serotonin System Genes ............................................................................. 20 1.7.4. Other Gene Systems ................................................................................... 22 vi Chapter Section Title Page 1.7.5. GWAS ........................................................................................................ 24 1.8. Genetics of Appetite and Weight Regulation ......................................... 25 1.8.1. A Summary on the Heritability of Body Weight .......................................
Recommended publications
  • Hippocampal Neurophysiology During Exploratory Behaviour and Sleep in Rats Heterozygous for the Psychiatric Risk Gene Cacna1c
    Hippocampal Neurophysiology During Exploratory Behaviour and Sleep in Rats Heterozygous for the Psychiatric Risk Gene Cacna1c Edward Richard Morrell A Thesis Presented for the Degree of Doctor of Philosophy December 2020 Word Count: 43,582 Abstract Genome-wide association studies reveal that calcium channel gene variants confer risk for psychiatric disorders across diagnostic categories. One consistently implicated gene is CACNA1C, a gene encoding the α1 pore-forming subunit of the L-type calcium channel. Recent rodent research highlights an important role for Cacna1c in hippocampal synaptic plasticity and related cognition, yet little is known about the effects of reduced Cacna1c gene dosage on hippocampal neurophysiology in vivo. Using tetrodes targeted to the dorsal CA1 I recorded single unit and local field potential activity in rats heterozygous for Cacna1c during free exploration and rest. Cacna1c heterozygous rats displayed enlarged place-fields and an associated reduction in place-cell spatial information content during runs on a linear track in a familiar and novel orientation, while place-cell activity during exploration of a novel open-field was intact. In addition, while 6-10Hz theta and 25-140Hz gamma rhythms were comparable in frequency and power in heterozygotes, their dependence on locomotion was compromised. Phase- amplitude coupling between theta and slow-gamma was also attenuated in Cacna1c heterozygous rats running on the track in a novel orientation. Hippocampal recordings at rest revealed intact 120-250Hz sharp-wave ripple oscillations, yet an enhanced participation of individual neurons in sharp-wave ripple events in Cacna1c heterozygotes. Despite the elevation in ripple-associated activity, coactivity between cell pairs during sharp-wave ripple events was markedly impaired.
    [Show full text]
  • Review Synaptic Functions and Their Disruption in Schizophrenia: from Clinical Evidence to Synaptic Optogenetics in an Animal Model
    No. 5] Proc. Jpn. Acad., Ser. B 95 (2019) 179 Review Synaptic functions and their disruption in schizophrenia: From clinical evidence to synaptic optogenetics in an animal model † By Kisho OBI-NAGATA,*1 Yusuke TEMMA*1 and Akiko HAYASHI-TAKAGI*1,*2, (Communicated by Nobutaka HIROKAWA, M.J.A.) Abstract: The adult human brain consists of approximately a hundred billion neurons, which are connected via synapses. The pattern and strength of the synaptic connections are constantly changing (synaptic plasticity), and these changes are considered to underlie learning, memory, and personality. Many psychiatric disorders have been related to disturbances in synaptogenesis and subsequent plasticity. In this review, we summarize findings of synaptic disturbance and its involvement in the pathogenesis and/or pathophysiology of psychiatric disorders. We will focus on schizophrenia, because this condition has a high proven heritability, which offers more unambiguous insights into the biological origins of not only schizophrenia but also related psychiatric disorders. To demonstrate the involvement of synaptopathy in psychiatric disorders, we discuss what knowledge is missing at the circuits level, and what new technologies are needed to achieve a comprehensive understanding of synaptopathy in psychiatric disorders. Keywords: synaptopathy, schizophrenia, synaptic integration, optogenetics, AS-PaRac1 tally alter neural outcomes. Epidemiological, devel- Introduction opmental and neuroimaging studies have indicated Human brain development is a protracted that
    [Show full text]
  • American Psychiatric Association 1999 Annualmeeting
    1999 SCIENTIFIC PROGRAM COMMITTEE Seated (left to right): Drs. Ordonca. Levin, Ruiz, Butterfield. Balon, Shaffi. 1st Row Standing (left to right): Drs. Belfer. Pena. Vergare, Pi. Spitz. Mega. McDowell. Goldfinger, Val, Lu, Tamminga. 2nd Row Standing (left to right): Drs. Ratner. Hamilton. Weissman. Ramox, Cutler. Dudley. Millman. Book. May 15,1999 Dear Colleagues and Guests: Welcome to the 152nd Annual Meeting of the American Psychiatric Association. This is the occasion when organized psychiatry displays its might in one of the largest educational, social and political medical gatherings in the world. The theme for 1999 is easy to remember, "The Clinician" I chose this theme because it represents the professional lives of most psychiatrists. I want to pay tribute to the attitudes, the skills and the knowledge of those who see patients day in and day out Research has given precision to our diagnoses and effectiveness to our treatments We are winning the war against anxiety and mood disorders, the psychoses, chemical dependence and the disorders resulting from structural damage to the brain. Psychotherapy and psychotropics are increasingly better targeted. We are going to dialogue about new initiatives in mental health financing. Radical reform is possible with the use of tax exemptions-vouchers, defined contributions (as opposed to the fine benefits), and consolidation of programs to enhance individual control. Our presentations here are going to show that the business community can join us in the protection of the working community. Employees are not costs but assets, the human capital is the best source of profits, and the employers should work better with physicians and not with insurance companies.
    [Show full text]
  • [For Consideration As Part of the ENIGMA Special Issue] Ten Years
    [For consideration as part of the ENIGMA Special Issue] Ten years of Enhancing Neuro-Imaging Genetics through Meta-Analysis: An overview from the ENIGMA Genetics Working Group Sarah E. Medland1,2,3, Katrina L. Grasby1, Neda Jahanshad4, Jodie N. Painter1, Lucía Colodro- Conde1,2,5,6, Janita Bralten7,8, Derrek P. Hibar4,9, Penelope A. Lind1,5,3, Fabrizio Pizzagalli4, Sophia I. Thomopoulos4, Jason L. Stein10, Barbara Franke7,8, Nicholas G. Martin11, Paul M. Thompson4 on behalf of the ENIGMA Genetics Working Group 1 Psychiatric Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia. 2 School of Psychology, University of Queensland, Brisbane, Australia. 3 Faculty of Medicine, University of Queensland, Brisbane, Australia. 4 Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Marina del Rey, CA, USA. 5 School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia. 6 Faculty of Psychology, University of Murcia, Murcia, Spain. 7 Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands. 8 Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands. 9 Personalized Healthcare, Genentech, Inc., South San Francisco, USA. 10 Department of Genetics & UNC Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, USA. 11 Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Abstract Here we review the motivation for creating the ENIGMA (Enhancing NeuroImaging Genetics through Meta Analysis) Consortium and the genetic analyses undertaken by the consortium so far. We discuss the methodological challenges, findings and future directions of the Genetics Working Group.
    [Show full text]
  • 2017 Annual Meeting Guide
    #APAAM17 psychiatry.org/ annualmeeting to the 2017 Annual Meeting Prevention Through Partnerships About This Guide psychiatry.org/annualmeeting In this book, you will find three sections: Program, New Research and the Exhibits Guide. Use these sections to navigate the 2017 Annual Meeting and experience all the meeting has to offer. Located within the Program, you will find a description of the various scientific session formats along with a log where you can record your daily attendance for the purpose of obtaining CME credit for your activities. The Program is first organized by day, then by session start time, with formats and sessions listed alphabetically under those times. Individual meeting days and program tracks are color- coded to make navigating the Program simple and easy. The New Research section lists the posters that will be presented at this meeting, organized numerically by session/day. There is a topic index at the end of the New Research section to assist you in finding the posters most interesting to you. The Exhibits Guide contains an acknowledgement to exhibitors for sponsorships, a list of the exhibitors and a floor plan of the Exhibit Hall, along with information about the Product Theaters, Therapeutic Updates, Career Fair, and Publishers Book Fair. Use this guide and the included exhibitor and author/presenter indices to navigate the exhibit hall and find precisely the booth you’re looking for. If you have any questions about this book or the scientific program, please feel free to stop by the Education Center, Ballroom 20 Foyer, Upper Level, San Diego Convention Center, and a member of the APA Administration will be happy to assist you.
    [Show full text]
  • Neurogenetic Plasticity and Sex Influence the Link Between
    www.nature.com/scientificreports OPEN Neurogenetic plasticity and sex infuence the link between corticolimbic structural Received: 18 May 2017 Accepted: 25 August 2017 connectivity and trait anxiety Published: xx xx xxxx M. Justin Kim, Reut Avinun, Annchen R. Knodt, Spenser R. Radtke & Ahmad R. Hariri Corticolimbic pathways connecting the amygdala and ventral prefrontal cortex (vPFC) are linked with trait anxiety, but it remains unclear what potential genetic moderators contribute to this association. We sought to address this by examining the inter-individual variability in neuroplasticity as modeled by a functional polymorphism (rs6265) in the human gene for brain derived neurotrophic factor (BDNF). Amygdala-vPFC pathway fractional anisotropy (FA) from 669 difusion magnetic resonance images was used to examine associations with trait anxiety as a function of rs6265 genotype. We frst replicated the inverse correlation between trait anxiety and amygdala-vPFC pathway FA in women. Furthermore, we found a moderating infuence of rs6265 genotype such that the association between trait anxiety and right amygdala-vPFC pathway FA was strongest in women carrying the Met allele, which is linked with decreased activity-dependent neuroplasticity. Results indicate that the microstructural integrity of pathways supporting communication between the amygdala and vPFC help shape the expression of trait anxiety in women, and that this association is further modulated by genetically driven variability in neuroplasticity. Neurobiological theories of anxiety postulate that an interconnected network of brain regions, which typically includes the amygdala1, the medial prefrontal cortex2, and the bed nucleus of the stria terminalis3, are central to the generation and regulation of anxious states. Of particular importance for the experience of anxiety are the dynamic reciprocal interactions between the amygdala and medial prefrontal cortex4, 5.
    [Show full text]
  • Psychiatric Genetics and the Structure of Psychopathology
    Molecular Psychiatry https://doi.org/10.1038/s41380-017-0010-4 EXPERT REVIEW Psychiatric genetics and the structure of psychopathology 1,2,3 4,5 6 7 7 Jordan W. Smoller ● Ole A. Andreassen ● Howard J. Edenberg ● Stephen V. Faraone ● Stephen J. Glatt ● Kenneth S. Kendler8,9 Received: 20 July 2017 / Revised: 23 October 2017 / Accepted: 1 November 2017 © Macmillan Publishers Limited, part of Springer Nature 2017 Abstract For over a century, psychiatric disorders have been defined by expert opinion and clinical observation. The modern DSM has relied on a consensus of experts to define categorical syndromes based on clusters of symptoms and signs, and, to some extent, external validators, such as longitudinal course and response to treatment. In the absence of an established etiology, psychiatry has struggled to validate these descriptive syndromes, and to define the boundaries between disorders and between normal and pathologic variation. Recent advances in genomic research, coupled with large-scale collaborative efforts like the Psychiatric Genomics Consortium, have identified hundreds of common and rare genetic variations that contribute to a range of neuropsychiatric disorders. At the same time, they have begun to address deeper questions about the structure and classification of mental disorders: To what extent do genetic findings support or challenge our clinical 1234567890 nosology? Are there genetic boundaries between psychiatric and neurologic illness? Do the data support a boundary between disorder and normal variation? Is it possible to envision a nosology based on genetically informed disease mechanisms? This review provides an overview of conceptual issues and genetic findings that bear on the relationships among and boundaries between psychiatric disorders and other conditions.
    [Show full text]
  • The Neurobiology of Mood and Psychotic Disorders Jacqueline A
    The Neurobiology of Mood and Psychotic Disorders Jacqueline A. Clauss, MD, PhD Clinical and Post-Doctoral Fellow, Division of Child and Adolescent Psychiatry, Department of Psychiatry, Massachusetts General Hospital Clinical Fellow, Division of Child and Adolescent Psychiatry, McLean Hospital Daphne Holt, MD, PhD Co-Director, Schizophrenia Clinical and Research Program Department of Psychiatry, Massachusetts General Hospital Associate Professor, Harvard Medical School www.mghcme.org Disclosures Neither I nor my spouse has a relevant financial relationship with a commercial interest to disclose. www.mghcme.org Disorder incidence and overlap • Major Depressive Disorder (MDD) Overall lifetime incidence: 17% in the U.S. (lower in other countries, e.g., in Japan 3%) Among those with MDD, lifetime incidence of psychosis: ~18% • Bipolar Disorder (BD) Overall lifetime incidence: ~4% (including Bipolar I & II and subthreshold); 1% for Bipolar I Among those with BD, lifetime incidence of psychosis: 25% • Schizophrenia (SZ) Overall lifetime incidence: 0.7%, ~3% defined broadly (with 5+ fold variation in incidence across the world, highlighting the importance of environmental factors) Among those with SZ, lifetime incidence of MDD: 25% • Genetics and neuroimaging studies show evidence for biological overlap and specificity (to symptoms or diagnostic category) Overlap vs. diagnostic specificity: Bipolar 1–linked genes overlap most with schizophrenia-linked genes, Bipolar II-linked genes overlap most with depression-linked genes The Bipolar Disorder
    [Show full text]
  • Psychiatric Genetics, Neurogenetics, and Neurodegeneration
    EDITORIAL published: 14 January 2015 doi: 10.3389/fgene.2014.00467 Psychiatric genetics, neurogenetics, and neurodegeneration Berit Kerner* Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA *Correspondence: [email protected] Edited and Reviewed by: Valerie Knopik, Rhode Island Hospital, USA Keywords: risk gene identification, functional genomic variants, social epigenetics, heterogeneity, pleiotropy, amyotrophic lateral sclerosis (ALS), genome-wide association studies (GWAS), environmental exposure Neuropsychiatric disorders are common, complex, and severe observation that variations in the same gene can influence several disorders that affect the core of a person: their emotions, intel- seemingly unrelated phenotypic traits. Heterogeneity describes lect, and ability to self-regulate. Millions of individuals world- the observation that the same disease can be caused by genetic wide suffer from these disorders; nevertheless, the factors that variationinanyoneofanumberofgenes.Theauthorsalsohigh- lead to the manifestation of symptoms are poorly understood. light recent successes in risk gene identification that were brought Neuropsychiatric disorders are characterized by heterogeneity, about with the help of next-generation sequencing in combi- which means that disorders with similar symptoms and disease nation with linkage studies and/or functional studies in small course do not necessarily share the same disease mechanisms or animals and cell cultures. Sequeira et al. explore
    [Show full text]
  • Can Noninvasive Brain Stimulation Enhance Cognition in Neuropsychiatric Disorders?
    Neuropharmacology 64 (2013) 566e578 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Invited review Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders? Asli Demirtas-Tatlidede a,*, Andrew M. Vahabzadeh-Hagh b, Alvaro Pascual-Leone b a Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey b Berenson-Allen Center for Noninvasive Brain Stimulation, Behavioral Neurology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA article info abstract Article history: Cognitive impairment is a core symptom of many neuropsychiatric diseases and a key contributor to the Received 3 April 2012 patient’s quality of life. However, an effective therapeutic strategy has yet to be developed. Noninvasive Received in revised form brain stimulation techniques, namely transcranial magnetic stimulation (TMS) and transcranial direct 11 June 2012 current stimulation (tDCS), are promising techniques that are under investigation for a variety of Accepted 12 June 2012 otherwise treatment-resistant neuropsychiatric diseases. Notably, these tools can induce alterations in neural networks subserving cognitive operations and thus may provide a means for cognitive restoration. Keywords: The purpose of this article is to review the available evidence concerning cognitive enhancing properties Noninvasive brain stimulation fi Repetitive transcranial magnetic of noninvasive brain stimulation in neuropsychiatry. We speci cally focus on major depression, Alz- ’ fi stimulation (TMS, rTMS) heimer s disease, schizophrenia, autism and attention de cit hyperactivity disorder (ADHD), where Transcranial direct current stimulation cognitive dysfunction is a major symptom and some studies have been completed with promising (tDCS) results.
    [Show full text]
  • The Rs6265 Polymorphism of the BDNF Gene Is Related to Higher-Lethality Suicide Attempts in the Korean Population
    ORIGINAL ARTICLE Print ISSN 1738-3684 / On-line ISSN 1976-3026 https://doi.org/10.30773/pi.2020.0012 OPEN ACCESS The rs6265 Polymorphism of the BDNF Gene Is Related to Higher-Lethality Suicide Attempts in the Korean Population Seung-Gul Kang1, Jong Hun Lee2, Kwanghun Lee3, Hee-Cheol Kim4, Wan Seok Seo5, and Seunghee Won6 1Department of Psychiatry, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea 2Department of Psychiatry, College of Medicine, Daegu Catholic University, Daegu, Republic of Korea 3Department of Psychiatry, College of Medicine, Dongguk University, Gyeongju, Republic of Korea 4Department of Psychiatry, Keimyung University School of Medicine, Daegu, Republic of Korea 5Department of Psychiatry, College of Medicine, Yeungnam University, Daegu, Republic of Korea 6Department of Psychiatry, School of Medicine, Kyungpook National University, Daegu, Republic of Korea Objective Since the risk of suicide cannot be predicted by clinical symptoms alone, and suicide is known to have a genetic component, the discovery of genetic markers that can predict the lethality of suicide attempts is a clinically important topic. There have been many studies aiming to determine whether the rs6265 polymorphism of the BDNF gene is associated with suicidality; however, the results have been mixed, and there have been few studies investigating the relationship between this polymorphism and suicide attempt lethality. Methods We assessed suicide lethality in 258 individuals who had attempted suicide using the relative risk ratio (RRR) scale and by ge- notyping the rs6265 polymorphism of the BDNF gene. Results The RRR score for suicide attempts was higher in subjects with Met/Val and Val/Val genotypes than in that with a Met/Met genotype (p=0.015).
    [Show full text]
  • The P-Factor and Its Genomic and Neural Equivalents: an Integrated Perspective
    Molecular Psychiatry https://doi.org/10.1038/s41380-021-01031-2 PERSPECTIVE The P-factor and its genomic and neural equivalents: an integrated perspective 1 2 1,3,4 Emma Sprooten ● Barbara Franke ● Corina U. Greven Received: 7 May 2020 / Revised: 1 December 2020 / Accepted: 13 January 2021 © The Author(s), under exclusive licence to Springer Nature Limited 2021. This article is published with open access Abstract Different psychiatric disorders and symptoms are highly correlated in the general population. A general psychopathology factor (or “P-factor”) has been proposed to efficiently describe this covariance of psychopathology. Recently, genetic and neuroimaging studies also derived general dimensions that reflect densely correlated genomic and neural effects on behaviour and psychopathology. While these three types of general dimensions show striking parallels, it is unknown how they are conceptually related. Here, we provide an overview of these three general dimensions, and suggest a unified interpretation of their nature and underlying mechanisms. We propose that the general dimensions reflect, in part, a combination of heritable ‘environmental’ factors, driven by a dense web of gene-environment correlations. This perspective 1234567890();,: 1234567890();,: calls for an update of the traditional endophenotype framework, and encourages methodological innovations to improve models of gene-brain-environment relationships in all their complexity. We propose concrete approaches, which by taking advantage of the richness of current large databases will help to better disentangle the complex nature of causal factors underlying psychopathology. Introduction psychopathology [3, 4], and a general dimension of brain structure and function [5, 6]. Here we refer to the general A trend has emerged that shows striking parallels between dimension derived from behavioural data as “phenotypic clinical psychology, psychiatric genetics and neuroima- P-factor”, the general dimension derived from genomic ging.
    [Show full text]